NCT00802906View on ClinicalTrials.gov

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2010

Conditions
Central Serous Chorioretinopathy
Interventions
DEVICE

subthreshold micropulselaser

on demand if leakage is persistent or recurs after initial treatment

DRUG

bevacizumab

1.5 mg initial intravitreal injection

Trial Locations (1)

60590

ZAU Department of VR surgery, Frankfurt am Main

All Listed Sponsors
lead

Johann Wolfgang Goethe University Hospital

OTHER

NCT00802906 - Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) | Biotech Hunter | Biotech Hunter